The role of allogeneic hematopoietic stem cell transplantation in the four P medicine era

참고문헌 (Reference)

1 Dyer G, "What they want: inclusion of blood and marrow transplantation survivor preference in the development of models of care for long-term health in Sydney, Australia" 22 : 731-743, 2016

2 DeFor TE, "Validation of a modified comorbidity index for allogeneic hematopoietic cell transplant" 128 (128): 2016

3 Giebel S, "Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosomepositive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation" 122 : 2941-2951, 2016

4 Passweg JR, "Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report" 52 : 811-817, 2017

5 Schindler T, "Structural mechanism for STI-571 inhibition of abelson tyrosine kinase" 289 : 1938-1942, 2000

6 El Cheikh J, "Risk-adapted approach to HLA-matched sibling hematopoietic cell allografting: impact of adjusting conditioning intensity and integrating post-transplant therapeutic interventions" 16 : 304-310, 2016

7 Tsirigotis P, "Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT" 51 : 1431-1438, 2016

8 Hood L, "Predictive, personalized, preventive, participatory (P4) cancer medicine" 8 : 184-187, 2011

9 Malagola M, "Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients" 5 : 265-274, 2016

10 ten Brink MH, "Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics" 19 : 1572-1586, 2014

11 Strebhardt K, "Paul Ehrlich's magic bullet concept: 100 years of progress" 8 : 473-480, 2008

12 Rioth MJ, "Next-generation long-term transplant clinics: improving resource utilization and the quality of care through health information technology" 51 : 34-40, 2016

13 Hashmi S, "Lost in transition: the essential need for long-term follow-up clinic for blood and marrow transplantation survivors" 21 : 225-232, 2015

14 D'Souza A, "Is 'informed consent' an 'understood consent' in hematopoietic cell transplantation?" 50 : 10-14, 2015

15 O'Brien SG, "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia" 348 : 994-1004, 2003

16 Gratwohl A, "Hematopoietic stem cell transplantation: a global perspective" 303 : 1617-1624, 2010

17 Niederwieser D, "Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey" 51 : 778-785, 2016

18 Sorror ML, "Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT" 106 : 2912-2919, 2005

19 Jacobsohn DA, "Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium" 120 : 2545-2552, 2012

20 Innes AJ, "Allogeneic transplantation for CML in the TKI era: striking the right balance" 13 : 79-91, 2016

21 Wagner EH, "A survey of leading chronic disease management programs: are they consistent with the literature?" 7 : 56-66, 1999